Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.99 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.86 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.86 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.86 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.86 |
| ▸ | STK10 | O94804 | 1/20 | 0.86 |
| ▸ | ABL1 | P00519 | 1/20 | 0.86 |
| ▸ | INSR | P06213 | 1/20 | 0.86 |
| ▸ | RET | P07949 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.86 |
| ▸ | SRC | P12931 | 1/20 | 0.86 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.86 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.86 |
| ▸ | CDK2 | P24941 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapatinib SCHEMBL571898 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29356338 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL30680457 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL15408126 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL4926017 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL93590 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29866632 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL31732815 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL1374543 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL1651711 | 0.95 | EGFR (0.91) | EGFRERBB2ABCB11MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3574906-B1 | SOLID PREPARATION COMPRISING QUINAZOLINE DERIVATIVE | SHIONOGI & CO (JP) | 2024-07-03 | — | — | EP | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| CN-113993515-B | Methods of treating solid tumors using crocetin | 杭州梦岚瑞思生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20220118057-A1 | ALBUMIN NANOPARTICLES, THE MAKING METHOD, AND USES THEREOF | NOVAGENESIS THERAPEUTIX (HK) LIMITED (CN) | 2022-04-21 | — | — | US | disclosed |
| CN-113993515-A | Methods of treating solid tumors using crocetin | 杭州梦岚瑞思生物科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113905722-A | Albumin nanoparticles, preparation method and application thereof | 锐创生物医药(香港)有限公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3330267-B1 | SALT OF QUINAZOLINE DERIVATIVE OR CRYSTAL THEREOF, AND METHOD FOR PRODUCING SALT OF QUINAZOLINE DERIVATIVE OR CRYSTAL THEREOF | SHIONOGI & CO (JP) | 2022-01-05 | — | — | EP | disclosed |
| US-20210401881-A1 | RADIATION/CHEMOTHERAPY SENSITIZER TO BE USED FOR INTRATUMORAL LOCAL INJECTION AND FOR CONTROLLED RELEASE OF HYDROGEN PEROXIDE WITH HYDROGEL AS CARRIER | KORTUC INC. (JP) | 2021-12-30 | — | — | US | disclosed |
| WO-2021114089-A1 | METHODS OF USING CROCETIN IN TREATING SOLID TUMORS | HANGZHOU MENGLANRUISI BIOTECHNOLOGY CO., LTD. (CN) | 2021-06-17 | — | — | WO | disclosed |
| EP-2958552-A1 | PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-(3-FLUOROBENZYLOXY)PHENYL]-6-[5({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]QUINAZOLIN-4-AMINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, SOLVATE OR SOLVATED SALT THEREOF | Hexal AG (DE) | 2015-12-30 | — | — | EP | disclosed |
| US-20150366905-A1 | RADIATION/CHEMOTHERAPY SENSITIZER TO BE USED FOR INTRATUMORAL LOCAL INJECTION AND FOR CONTROLLED RELEASE OF HYDROGEN PEROXIDE WITH HYDROGEL AS CARRIER | KORTUC INC. (JP) | 2015-12-24 | — | — | US | disclosed |
| EP-2957287-A1 | RADIATION/CHEMOTHERAPY SENSITIZER TO BE USED FOR INTRATUMORAL LOCAL INJECTION AND FOR CONTROLLED RELEASE OF HYDROGEN PEROXIDE WITH HYDROGEL AS CARRIER | Kochi University (JP) | 2015-12-23 | — | — | EP | disclosed |
| US-20140335177-A1 | PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-8821927-B2 | Pharmaceutical composition | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2014-09-02 | — | — | US | disclosed |
| WO-2014128107-A1 | PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-(3-FLUOROBENZYLOXY)PHENYL]-6-[5({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]QUINAZOLIN-4-AMINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, SOLVATE OR SOLVATED SALT THEREOF | HEXAL AG (DE) | 2014-08-28 | — | — | WO | disclosed |
| US-20090203718-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LTD. (IE) | 2009-08-13 | — | — | US | disclosed |
| US-20080206330-A1 | 4-quinazolinamine active ingredient; inhibitor of EGFR and erbB2 protein tyrosine kinase; cancer; tablets manufactured economically, conveniently shipped, stored, dispensed; accurate dosage, ease of administration, portability | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| EP-1871347-A1 | PHARMACEUTICAL COMPOSITION | SmithKline Beecham (Cork) Limited (IE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006113649-A1 | PHARMACEUTICAL COMPOSITION | SMITHKLINE BEECHAM [CORK] LIMITED (IE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203718-A1 | CANCER TREATMENT METHOD | IGF1R, EGFR, ERBB2 | EGFR 2/4885ERBB2 3/4885ABCB11 3281/4885 |
| US-20220118057-A1 | ALBUMIN NANOPARTICLES, THE MAKING METHOD, AND USES THEREOF | KRAS, ALB, TP53 | EGFR 402/4885ERBB2 996/4885ABCB11 1101/4885 |
| US-20140335177-A1 | PHARMACEUTICAL COMPOSITION | ERBB2, ERBB4, ERBB3 | EGFR 28/4885ERBB2 1/4885ABCB11 709/4885 |
| US-20080206330-A1 | 4-quinazolinamine active ingredient; inhibitor of EGFR and erbB2 protein tyrosine kinase; cancer; tablets manufactured economically, conveniently shipped, stored, dispensed; accurate dosage, ease of administration, portability | ERBB2, ERBB4, PTK2B | EGFR 18/4885ERBB2 1/4885ABCB11 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.